Abstract No. 29 Varian Velocity 4.0’s RapidSphere dosimetry assessment in predicting treatment outcomes following Yttrium-90 transarterial radioembolization (TARE) of hepatic tumors

Abstract

To date, there is not a validated method by which absorbed yttrium-90 (Y-90) by hepatic tumors and liver parenchyma can be calculated immediately following transarterial radioembolization (TARE). Instead, treatment response is measured using MRI or CT several weeks to months following treatment compared with pre-treatment baseline imaging. Although this evaluation is useful in the long-term management of patients with malignant hepatic disease, it delays the opportunity for immediate rectification in cases where radiation delivered to hepatic tumors was insufficient.